Study guide
Neovascular, uveitic and steroid-response glaucoma
European Board of Ophthalmology Diploma EBOD
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: EBOD Examination, Applications and Regulations
EBOD Format, Scoring and Revision Planning Eligibility, Applications and the Diploma Online Rules, Technical Preparation and Appeals
2 Chapter 2: Physical Optics, Photometry and Lenses
Light, refraction and total internal reflection Photometry, contrast, colour and adaptation Prisms, decentration and vector combination Vergence, astigmatic lenses and Sturm’s conoid
3 Chapter 3: Instrument Optics, Aberrations and Laser Physics
Cross-cylinder and diagnostic instrument optics Aberrations, duochrome and wavefront analysis Diffraction, polarization, lasers and OCT
4 Chapter 4: Refraction, Accommodation and Spectacle Prescribing
Objective and cycloplegic refraction Subjective refraction and binocular balance Accommodation, presbyopia and vertex distance Spectacle Materials, Measurement and Progressive Lenses
5 Chapter 5: Contact Lenses and Low-Vision Rehabilitation
Contact-lens optics, materials and tear lenses Contact-lens fit and complications Low-vision assessment and magnification Low-vision aids, calculations and ergonomics
6 Chapter 6: Extraocular Anatomy and Motor Physiology
Extraocular muscle anatomy and innervation Eye axes, kinematics and muscle actions Motor laws and orbital pulleys
7 Chapter 7: Binocular Vision and Amblyopia
Binocular vision, stereopsis and the horopter Suppression, correspondence and microtropia Sensory tests and amblyopia treatment
8 Chapter 8: Childhood Assessment and Strabismus Testing
Visual Development, Childhood Testing and Developmental Delay History, corneal reflexes and cover tests Motility patterns, three-step testing and Hess charts
9 Chapter 9: Esotropia, Exotropia and Vertical Deviations
Infantile and accommodative esotropia Exotropia classification and management Vertical Deviations, A–V Patterns and Skew
10 Chapter 10: Dysinnervation, Nystagmus and Muscle Surgery
Duane syndrome, Brown syndrome and restriction Nystagmus patterns and investigation Nystagmus and muscle surgery principles
11 Chapter 11: ROP and Paediatric Ocular Disease
Retinopathy of Prematurity: Screening, Classification and Follow-up Childhood Cataract, Leukocoria and Congenital Glaucoma Childhood Systemic Disease, Infection and Safeguarding
12 Chapter 12: Ocular Surface Anatomy and Infection
Corneal, Conjunctival and Scleral Structure: Examination and Sampling Bacterial keratitis, sampling and treatment Fungal, amoebic and herpetic keratitis Infectious, chlamydial and neonatal conjunctivitis
13 Chapter 13: Allergy, Cicatrisation and Surface Inflammation
Allergic eye disease, trachoma and phlyctenules Cicatrising Conjunctivitis: Mucous Membrane Pemphigoid and SJS/TEN Dry eye, blepharitis and meibomian dysfunction PUK, interstitial keratitis and scleritis
14 Chapter 14: Anterior Segment Dysgenesis and Corneal Dystrophies
Anterior Segment Dysgenesis, Aniridia and Congenital Corneal Opacity IC3D and epithelial or Bowman-layer dystrophies Stromal corneal dystrophies Endothelial corneal dystrophies
15 Chapter 15: Corneal Degeneration, Ectasia and Epithelial Failure
Corneal Degenerations, Pterygium, Band Keratopathy and Dellen Keratoconus and clinical ectasia signs Ectasia imaging, cross-linking and rehabilitation Recurrent Erosion, Neurotrophic Keratopathy and Vitamin A Deficiency
16 Chapter 16: Surface Reconstruction and Keratoplasty
Limbal Stem-Cell Failure, Tarsorrhaphy and Phototherapeutic Keratectomy PK, DALK and endothelial keratoplasty Corneal graft immunity and rejection recognition Graft rejection treatment and postoperative problems
17 Chapter 17: Lens Development, Cataract Assessment and Biometry
Lens Development, Congenital Shape and Ectopia Lentis Lens anatomy and age-related cataract phenotypes Cataract grading, secondary causes and childhood disease Optical and ultrasound biometry
18 Chapter 18: IOL Planning and Phacoemulsification
Keratometry and IOL power formulae Post-refractive biometry, toric alignment and IOL design Phaco fluidics and ultrasound delivery Wounds, OVDs and nucleus techniques
19 Chapter 19: Cataract Anaesthesia and Surgical Complications
Cataract Anaesthesia, Alternative Extraction and Combined Procedures IFIS, capsule rupture and compromised support Postoperative inflammation, haemorrhage and PCO
20 Chapter 20: Corneal and Intraocular Refractive Surgery
Excimer ablation, PRK and LASIK SMILE, surgical selection and complications Phakic IOLs and refractive lens exchange
21 Chapter 21: Presbyopia Procedures and Surface Therapeutics
Presbyopia Surgery, Monovision and Historical Refractive Procedures Surface antimicrobial and anti-inflammatory pharmacology Surface healing, amnion and cenegermin
22 Chapter 22: Aqueous Dynamics, Tonometry and Gonioscopy
Ciliary body and aqueous secretion Outflow and the Goldmann pressure model Tonometry, corneal thickness and biomechanics Gonioscopy optics, landmarks and indentation
23 Chapter 23: Angle, Disc and Visual-Field Assessment
Angle grading and anterior-segment imaging Optic-disc examination and documentation OCT and automated perimetry
24 Chapter 24: Glaucoma Progression, Suspects and Secondary Mechanisms
Field reliability and progression Ocular hypertension, suspects and juvenile glaucoma Lens-related glaucoma, aqueous misdirection and venous pressure
25 Chapter 25: POAG, Angle Closure and Pigmentary Disease
POAG, target pressure and normal-tension disease Angle-closure classification and mechanisms Acute angle closure, iridotomy and lens extraction Pseudoexfoliation and pigmentary glaucoma
26 Chapter 26: Glaucoma Medical, Laser and Surgical Treatment
Neovascular, uveitic and steroid-response glaucoma Glaucoma medicines, SLT and MIGS Trabeculectomy and drainage implants Nonpenetrating surgery, cyclodestruction and postoperative lasers
27 Chapter 27: Retinal Imaging, Diabetes and Vascular Occlusion
Retinal anatomy, examination and multimodal imaging Diabetic microangiopathy and NPDR classification PDR, macular oedema and diabetic trials Retinal vein and artery occlusions
28 Chapter 28: Uncommon Vascular Disease and Myopic Maculopathy
Macroaneurysm, sickle retinopathy and retinal periphlebitis Coats disease and leukocoria assessment MacTel and radiation retinopathy Myopic maculopathy and presumed ocular histoplasmosis
29 Chapter 29: Inherited Retina and Electrophysiology
Retinitis pigmentosa and inherited degeneration Stargardt, Best disease and retinal electrophysiology Cone disorders, stationary night blindness and syndromic retina
30 Chapter 30: AMD, Geographic Atrophy and Pachychoroid
AMD biology and clinical staging Drusen, geographic atrophy and neovascular phenotypes Neovascular AMD trials and treatment CSCR and the pachychoroid spectrum
31 Chapter 31: Retinal Breaks and Detachment Repair
PVD, peripheral degenerations and retinal breaks RRD localization and retinoschisis Detachment mechanisms, pneumatic retinopexy and scleral buckling
32 Chapter 32: Vitrectomy, Macular Surgery and Retinal Trauma
Vitrectomy and intraocular tamponades ERM, macular holes and PVR Retinal trauma, optic-disc pits and choroidal detachment
33 Chapter 33: Uveitis Classification and Non-Infectious Inflammation
SUN classification, grading and uveitis work-up Anterior and intermediate uveitis patterns HLA-B27, sarcoidosis, Behçet disease and VKH Posterior inflammatory patterns and immunomodulation
34 Chapter 34: Infectious Uveitis and Endophthalmitis
Toxoplasmosis and herpetic necrotizing retinitis Ocular syphilis and tuberculosis Immunosuppressed retinitis, toxocariasis and neuroretinitis Endophthalmitis diagnosis and treatment
35 Chapter 35: Optic Neuritis and Ischaemic Optic Neuropathy
Typical optic neuritis and ONTT NMOSD and MOGAD Arteritic optic neuropathy and GCA NAION and ischaemic neuropathy comparison
36 Chapter 36: Papilloedema, IIH and Afferent Localisation
Papilloedema recognition and Frisén grading IIH diagnosis and vision protection Disc drusen and pseudopapilloedema Afferent pathways and chiasmal localization
37 Chapter 37: Congenital, Inherited and Cortical Neuro-Ophthalmology
Cortical vision and higher visual syndromes Neuro-ophthalmic testing and congenital optic discs Inherited, compressive, infiltrative and nutritional optic neuropathies Transient visual loss, headache and neurological emergencies
38 Chapter 38: Central Motor Control and Cranial Nerve Palsies
Central ocular motor control and supranuclear disorders Third- and fourth-nerve palsies Sixth nerve, pontine gaze and cavernous sinus
39 Chapter 39: Myasthenia and Ocular Myopathy
Myasthenic ocular weakness Myasthenia testing and treatment Myopathy, CPEO and Kearns–Sayre syndrome
40 Chapter 40: Pupillary Pathways and Anisocoria
Pupillary pathways and afferent defects Horner syndrome and tonic pupil Light–near dissociation and pupil differentials
41 Chapter 41: Orbit, Thyroid Eye Disease and Ptosis Assessment
Orbital anatomy and thyroid eye disease Orbital infection and idiopathic inflammation Orbital masses, approaches and eye-removal procedures Lid anatomy and ptosis evaluation
42 Chapter 42: Lid Repair and Lacrimal Drainage
Ptosis repair, malposition and eyelid tumours Lash disorders, facial palsy and lid reconstruction Lacrimal drainage and epiphora testing Nasolacrimal obstruction, infection and DCR
43 Chapter 43: Lacrimal Gland Disease, Pathology and Intraocular Tumours
Lacrimal gland inflammation and tumours Ocular histology, specimen handling and special stains Immunophenotyping, molecular pathology and tumour genetics Uveal melanoma and retinoblastoma
44 Chapter 44: Lymphoma, Surface Tumours and Paraneoplastic Disease
Vitreoretinal lymphoma Surface tumours, uveal metastases and benign mimics Paraneoplastic retinopathy, treatment effects and counselling
45 Chapter 45: Ocular Trauma and Vascular Systemic Disease
Trauma terminology and prognostic scoring Chemical injury and surface preservation Open-globe emergency management Vascular, endocrine, pregnancy and renal eye disease
46 Chapter 46: Multisystem Disease and Ophthalmic Pharmacology
Immune, metabolic and multisystem ocular clues Phakomatoses and syndrome-specific surveillance Connective-tissue and metabolic ocular disease Drug delivery and systemic glaucoma effects
47 Chapter 47: Medication Toxicity, Professional Practice and Clinical Stations
Retinal and optic medication toxicity Prevention, consent and professional practice Directed clinical answers and station rehearsal
Neovascular, uveitic and steroid-response glaucoma
Key Takeaways Explain This Topic AI
Neovascular disease requires treatment of retinal ischaemia as well as pressure and angle complications.
Inflammatory glaucoma can combine trabecular dysfunction, synechiae and steroid response.
Control inflammation and infection appropriately while selecting pressure treatment for the actual mechanism.
Last updated: October 2026
Neovascular Glaucoma (NVG)
Neovascular glaucoma is an aggressive, vision-threatening secondary glaucoma caused by anterior segment ischemia-induced neovascularization, culminating in fibrovascular closure of the iridocorneal filtration angle.
Etiological Mechanisms
NVG is triggered by severe, widespread posterior segment retinal hypoxia, which stimulates the overproduction and intraocular secretion of Vascular Endothelial Growth Factor (VEGF) and basic fibroblast growth factor (bFGF). These diffusible angiogenic cytokines travel into the posterior chamber and diffuse forward through the pupil into the anterior chamber, inciting pathological neovascularization across the iris stroma and trabecular meshwork. Primary ischemic causes include:
Proliferative Diabetic Retinopathy (PDR) : A major cause of retinal ischaemia driving NVG; the proportion of cases varies by referral population.
Ischaemic Central Retinal Vein Occlusion (CRVO) : A major cause of anterior-segment neovascularisation. The conventional CVOS definition used at least 10 10 10 disc areas of capillary non-perfusion on seven-field angiography; this is not ten disc diameters or a directly interchangeable ultra-widefield threshold. The label “100-day glaucoma” is historical: neovascularisation can arise earlier or later, so monitor the iris and angle according to risk and course.
Ocular Ischemic Syndrome (OIS) : Accounts for 10% to 15% of cases; secondary to severe internal carotid artery stenosis or ophthalmic artery occlusion. Because ciliary hypoperfusion impairs aqueous production, IOP may initially remain normal or low despite angle neovascularization, skyrocketing once anterior chamber perfusion is re-established.
The Four Clinical Stages of NVG
Stage 1: Pre-Glaucoma (Rubeosis Iridis) : Earliest visible sign: delicate, tiny tufts of microvascular capillaries appear at the pupillary border (often at 12:00 or 6:00 o'clock) and on the trabecular meshwork; the anterior chamber angle remains gonioscopically open; IOP is normal.
Stage 2: Open-Angle NVG : Neovascular vessels cross the scleral spur and arborize profusely across the trabecular meshwork, accompanied by an invisible, translucent fibrovascular membrane composed of myofibroblasts and collagen. This membrane physically covers and plugs the trabecular spaces, causing severe IOP elevation while the angle remains gonioscopically open.
Stage 3: Angle-Closure NVG : Myofibroblasts within the fibrovascular membrane contract, pulling the peripheral iris forward over the trabecular meshwork in a progressive, zipper-like synechial closure ( 360 ∘ 360^\circ 36 0 ∘ PAS) . The pupil exhibits marked ectropion uveae (eversion of the posterior pigmented iris epithelium onto the anterior iris surface). IOP escalates dramatically (often 50–70 mmHg), accompanied by severe corneal microcystic edema, intense ciliary flush, and agonizing pain.
Stage 4: Absolute Glaucoma : Terminal, irreversible stage characterized by a completely blind eye (no light perception), intractable pain, bullous keratopathy, and dense anterior segment fibrovascular scarring.
Multi-Modal Treatment Protocol
Immediate Anti-VEGF Therapy : Intravitreal administration of an anti-VEGF agent (aflibercept, ranibizumab, or bevacizumab) induces rapid, dramatic regression of iris and angle neovascularization within 24 to 48 hours. This temporarily quenches active bleeding and clears the anterior chamber, serving as an indispensable pharmacological bridge to definitive laser or surgery.
Retinal treatment : PRP reduces the angiogenic drive in appropriate ischaemic disease. Anti-VEGF is an adjunct, not a guarantee of permanent regression. If media opacity prevents laser, specialist options may include later laser, vitrectomy/endolaser or other approaches selected by anatomy and visual potential.
Uveitic Glaucoma & Corticosteroid-Induced Glaucoma
Elevated intraocular pressure in patients with intraocular inflammation involves complex mixed open-angle and closed-angle mechanisms.
Mechanisms of Uveitic Glaucoma
Open-Angle Uveitic Glaucoma :
Acute Trabeculitis : Direct inflammatory swelling and endothelial dysfunction of the trabecular meshwork lamellae (characteristic of herpes simplex, varicella zoster, cytomegalovirus anterior uveitis, and Posner-Schlossman syndrome [glaucomatocyclitic crisis] ).
Mechanical Outflow Blockage : Accumulation of inflammatory cells (polymorphonuclear leukocytes and macrophages), fibrin, and proteinaceous exudates within the intertrabecular spaces.
Aqueous Hyperviscosity : Severe breakdown of the blood-aqueous barrier elevates aqueous protein concentration, impeding outflow.
Closed-Angle Uveitic Glaucoma :
Pupillary Block via Seclusio Pupillae : Fibrovascular adhesions bind the entire pupillary margin 360 ∘ 360^\circ 36 0 ∘ to the anterior lens capsule ( annular posterior synechiae ), blocking aqueous transit from the posterior to the anterior chamber. The resulting trapped posterior chamber pressure balloons the peripheral iris forward ( iris bombé ), causing acute or subacute angle closure.
Non-Pupillary Block Angle Closure : Forward rotation of the ciliary body resulting from supraciliary effusion and choroidal detachment (e.g., in Vogt-Koyanagi-Harada syndrome); or progressive "creeping" peripheral anterior synechiae (PAS) caused by chronic organization of inflammatory exudates in the angle.
Medical Therapy & Absolute Contraindications in Uveitis
Anti-Inflammatory Control : Aggressive topical corticosteroids (Prednisolone acetate 1% or Dexamethasone 0.1%) are mandatory to suppress the primary inflammatory stimulus.
Aqueous Suppressants : Topical beta-blockers, alpha-2 agonists, and carbonic anhydrase inhibitors.
Mydriatic-Cycloplegics : Topical Atropine 1% or Cyclopentolate 1% are essential to paralyze the ciliary muscle (relieving pain and ciliary spasm), break early posterior synechiae, and prevent seclusio pupillae.
ABSOLUTE CONTRAINDICATIONS :
Pilocarpine and Cholinergic Miotics : Strictly contraindicated . Pilocarpine breaks down the blood-aqueous barrier, exacerbates intraocular inflammation, causes severe ciliary spasm, and accelerates the formation of broad, irreversible posterior and anterior synechiae.
Prostaglandin Analogues : Must be used with extreme caution in active uveitis due to their theoretical propensity to exacerbate anterior segment inflammation, trigger cystoid macular edema (CME), and reactivate latent herpes simplex keratitis.
Corticosteroid-Induced Glaucoma (Steroid Response)
Corticosteroids administered via topical, periocular, intraocular, inhaled, or systemic routes can trigger severe secondary open-angle ocular hypertension.
Pathophysiological Mechanism : Glucocorticoid receptor activation in trabecular meshwork cells causes transcriptional upregulation and accumulation of the glycoprotein myocilin ( MYOC ) , promotes the deposition of glycosaminoglycans and extracellular matrix in the juxtacanalicular meshwork, induces rearrangement of the trabecular cytoskeleton into cross-linked actin networks (CLANs), and suppresses endothelial phagocytic activity, drastically increasing conventional outflow resistance.
The Armaly-Becker Classification of Genetic Susceptibility :
High Responders : Approximately 5% of the general population develop an IOP increase > 15 >15 > 15 mmHg or an absolute IOP exceeding 31 mmHg after 2 to 4 weeks of topical steroid therapy.
Intermediate Responders : Approximately 30% of individuals exhibit an IOP elevation of 6 to 15 mmHg.
Non-Responders : Approximately 65% experience an IOP increase of < 6 <6 < 6 mmHg.
Risk: Established glaucoma, family history and some paediatric/systemic factors increase susceptibility, but a “greater than 90% high responder” rule is unsupported. Monitor pressure during treatment.
Steroid Formulation Risk : Intravitreal triamcinolone acetonide and intraocular implants (dexamethasone [Ozurdex], fluocinolone [Iluvien]) pose the greatest hypertensive risk, followed by potent topical steroids (difluprednate, prednisolone acetate 1%, dexamethasone 0.1%). "Soft" site-specific steroids (e.g., loteprednol etabonate, fluorometholone ) carry a markedly lower propensity for IOP elevation due to rapid enzymatic deactivation into inactive carboxylic acid metabolites.
Interpreting Secondary Mechanisms
LOXL1 variants are associated with PEX but are not diagnostic and do not justify routine folate treatment. PDS may become less active with age, yet pressure and damage still need monitoring; iridotomy can alter iris configuration without established prevention of glaucoma in every PDS patient. For NVG, treat retinal ischaemia and its systemic cause, use anti-VEGF as an adjunct and select laser and surgery by the eye. Conventional CRVO nonperfusion criteria use disc areas and a specified imaging field. Steroid responders vary; not all POAG patients or relatives are high responders. FML is a corticosteroid with pressure risk, not a metabolically inactive ester. In uveitic glaucoma, distinguish active inflammation, steroid response and infection. Avoid withdrawing needed anti-inflammatory treatment indiscriminately.